---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-008127"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2025-01-31T23:59:59+00:00"
generated_at: "2026-05-27T04:36:10.785621+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cellectar receives Nasdaq minimum bid price deficiency notice; 180-day cure period until July 29, 2025

## Summary
- Notice from Nasdaq on Jan 30, 2025 for failure to maintain $1.00 minimum bid price per Nasdaq Listing Rule 5550(a)(2).
- No immediate impact on listing; common stock remains on Nasdaq Capital Market.
- Company has 180 calendar days, until July 29, 2025, to regain compliance.
- If not cured, Company may be eligible for an additional 180-day extension subject to meeting other listing standards.
- Failure to regain compliance could lead to delisting; Company may request a hearing to stay any delisting action.

## SEC filing metadata
- accession: 0001104659-25-008127
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2025-01-31T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465925008127/0001104659-25-008127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465925008127/tm255128d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-008127
- JSON: https://secwatch.observer/filing/0001104659-25-008127.json
- Plain text: https://secwatch.observer/filing/0001104659-25-008127.txt

## Source-grounded claims
- claim_id: 71a6f457017afe085333d1905fc3fc69191dec60
  claim: Cellectar Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  evidence_excerpt: January 30, 2025, Cellectar Biosciences, Inc. (the “Company”) received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid price for its common
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465925008127/0001104659-25-008127-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.